共 232 条
[1]
Fauser BC(2012)Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group Fertil Steril 97 28-38
[2]
Tarlatzis BC(2015)American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome—part 1 Endocr Pract 21 1291-1300
[3]
Rebar RW(2014)Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis Hum Reprod Updat 20 748-758
[4]
Legro RS(2015)American Association of Clinical Endocrinologists, American College of Endocrinology, and androgen excess and PCOS society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome—part 2 Endocr Pract 21 1415-1426
[5]
Balen AH(2004)Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome JCEM 89 1273-1276
[6]
Lobo R(2016)Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies Hum Reprod 31 2619-2631
[7]
Carmina E(2012)Polycystic ovary syndrome is a risk factor for type 2 diabetes: results from a long-term prospective study Diabetes 61 2369-2374
[8]
Chang J(1997)Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis Endocr Rev 18 774-800
[9]
Yildiz BO(2015)Pancreatic β-cell dysfunction in polycystic ovary syndrome: role of hyperglycemia-induced nuclear factor-kB activation and systemic inflammation Am J Physiol Endocrinol Metab 308 E770-E777
[10]
Laven JS(1994)Studies of the nature of 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism JCEM 79 1686-1692